Pituitary tumors: pathophysiology, clinical manifestations and management

被引:125
作者
Arafah, BM
Nasrallah, MP
机构
[1] Univ Hosp Cleveland, Div Clin & Mol Endocrinol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Div Clin & Mol Endocrinol, Cleveland, OH 44106 USA
关键词
D O I
10.1677/erc.0.0080287
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pituitary tumors are frequently encountered intracranial neoplasms. They present with a variety of clinical manifestations that include symptoms and signs of excessive hormone secretion by the tumor, signs of hormone deficits by the normal pituitary gland and others related to expansion of the tumor mass and the resulting compression of surrounding structures such as the optic chiasm and cranial nerves. Advances in molecular biology, immunocytochemical staining and imaging, and the introduction of new treatment options have improved our understanding of the natural history of these adenomas and their management. Available treatments include surgical, medical and radiation therapy. Although the primary treatment for each tumor type may vary, it is important to consider all available options and select the most applicable for that patient. The interaction of all members of management team, including the primary care provider, the endocrinologist and the neurosurgeon in selecting the treatment course can only improve therapeutic outcome. Regardless of the initial choice of treatment, follow-up of all patients should be maintained indefinitely. The managing physician should be familiar with the natural history and long-term complications of pituitary adenomas, and with the side effects of treatments given over the years.
引用
收藏
页码:287 / 305
页数:19
相关论文
共 92 条
  • [61] A single midnight serum cortisol measurement distinguishes Cushing's syndrome from pseudo-Cushing states
    Papanicolaou, DA
    Yanovski, JA
    Cutler, GB
    Chrousos, GP
    Nieman, LK
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (04) : 1163 - 1167
  • [62] Growth hormone receptor antagonists therapy for acromegaly
    Parkinson, C
    Trainer, PJ
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 13 (03) : 419 - 430
  • [63] RADIOTHERAPY FOR PITUITARY-TUMORS
    PLOWMAN, PN
    [J]. BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1995, 9 (02): : 407 - 420
  • [64] Outcome of radiotherapy for acromegaly using normalization of insulin-like growth factor I to define cure
    Powell, JS
    Wardlaw, SL
    Post, ED
    Freda, PU
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (05) : 2068 - 2071
  • [65] TESTOSTERONE-RELATED EXACERBATION OF A PROLACTIN-PRODUCING MACROADENOMA - POSSIBLE ROLE FOR ESTROGEN
    PRIOR, JC
    COX, TA
    FAIRHOLM, D
    KOSTASHUK, E
    NUGENT, R
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1987, 64 (02) : 391 - 394
  • [66] Late-night salivary cortisol as a screening test for Cushing's syndrome
    Raff, H
    Raff, JL
    Findling, JW
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (08) : 2681 - 2686
  • [67] GLYCOPROTEIN-SECRETING PITUITARY-ADENOMAS
    SAMUELS, MH
    RIDGWAY, EC
    [J]. BAILLIERES CLINICAL ENDOCRINOLOGY AND METABOLISM, 1995, 9 (02): : 337 - 358
  • [68] GROWTH HORMONE-RELEASING HORMONE-PRODUCING TUMORS - CLINICAL, BIOCHEMICAL, AND MORPHOLOGICAL MANIFESTATIONS
    SANO, T
    ASA, SL
    KOVACS, K
    [J]. ENDOCRINE REVIEWS, 1988, 9 (03) : 357 - 373
  • [69] SHAHI M, 1992, BRIT HEART J, V67, P92
  • [70] Management of pituitary tumors
    Shimon, I
    Melmed, S
    [J]. ANNALS OF INTERNAL MEDICINE, 1998, 129 (06) : 472 - 483